ERBB2 and breast cancer: Taken together, our findings identify JNK as a potential target using the JIMT-1 and a BT474-LR HER2-inhibitor resistant breast cancer models and we put forward a potential combination strategy that applies co-targeting of JNK and HUNK kinases.